suPAR aims to predict kidney disease such as the early detection of cardiovascular disease will be predicted by cholesterol. suPAR, abbreviated as soluble urokinase-type plasminogen activator receptor is the soluble form of uPAR. It is a membrane-bound receptor for urokinase as well as Vitronectin. The cleavage and release of membrane-bound uPAR result in suPAR.

Chronic kidney disease causes approximately 47,000 deaths a year and is alluded to as a silent killer since most patients do not recognize they have it till the condition is well advanced. Currently, Healthcare professionals rely on Estimated Glomerular filtration rate (eGFR) and Proteinuria to detect and manage chronic kidney disease but they are not sensitive enough to detect the disease in its early stages or to predict a person's risk of developing the disease.

suPAR primarily acts as a biomarker for activation of the inflammatory and immune systems. Recent studies revealed that it can accurately predict the risk of a person developing chronic kidney disease for as much as five years before the disease begins to cause harm. It was found that a high suPAR level was an excellent predictor of future kidney disease. suPAR was also shown to predict eGFR decline in the patients with previously identified earlier stage kidney disease. Scientists continue to explore suPAR to identify protein variants that are associated with multiple types of chronic kidney disease.

Journal of Clinical & Experimental Nephrology focuses on the dissemination of the latest advancements on the current knowledge on all the aspects of Nephrology such as Peritoneal Dialysis, Kidney Diseases, Acute Renal Replacement Therapy, Chronic Kidney Disease, End-Stage Renal Diseases, Lupus Nephritis and Renal Transplantation.

Regards,

Calvin Parker
Journal of Clinical & Experimental Nephrology
WhatsApp: +32-2-808-66-57
E-mail id: nephrology@peerjournal.org